← Back to Clinical Trials
Recruiting NCT07189117

NCT07189117 Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07189117
Status Recruiting
Phase
Sponsor University Hospital, Basel, Switzerland
Condition Hematologic Malignancy
Study Type OBSERVATIONAL
Enrollment 350 participants
Start Date 2025-10-29
Primary Completion 2035-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 350 participants in total. It began in 2025-10-29 with a primary completion date of 2035-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study investigates how metabolism in cancer and immune cells shapes the bone marrow environment, influences therapy resistance, and affects outcomes in hematological malignancies.

Eligibility Criteria

Inclusion Criteria: * age \> 18 years, * signed written informed consent * For participants with hematological cancers: diagnosis of MDS, AML, ALL, PMF or post-ET/PV MF Exclusion Criteria: * pregnant or lactating women, * inability to give consent, * active malignant disease (other than MDS, AML, ALL, PMF or post-ET/PV MF in the last 3 - years prior to study inclusion). * For healthy donors: previous or current hematological disease, previous or current other malignant disease,

Contact & Investigator

Central Contact

Petya Apostolova, Prof. Dr.

✉ petya.apostolova@unibas.ch

📞 +41 61 328 48 40

Principal Investigator

Petya Apostolova, Prof. Dr.

STUDY CHAIR

University Hospital of Basel

Frequently Asked Questions

Who can join the NCT07189117 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07189117 currently recruiting?

Yes, NCT07189117 is actively recruiting participants. Contact the research team at petya.apostolova@unibas.ch for enrollment information.

Where is the NCT07189117 trial being conducted?

This trial is being conducted at Basel, Switzerland.

Who is sponsoring the NCT07189117 clinical trial?

NCT07189117 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Petya Apostolova, Prof. Dr. at University Hospital of Basel. The trial plans to enroll 350 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology